As of November 8, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Precision BioSciences, Inc. The largest reported stake is Matthew Smith's, at 9.4%. 17 filings are on record since August 6, 2025 (Schedule 13G/A, August 14, 2025).
Sell to companies like Precision BioSciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Octagon Capital Advisors LP · Sole voting: 0 · Shared voting: 1,651,497 · Sole dispositive: 0 · Shared dispositive: 1,651,497 · SCHEDULE 13G/A, 2026-11-03
- · Reporting person: BlackRock, Inc. · Sole voting: 1,349,236 · Shared voting: 0 · Sole dispositive: 1,384,230 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-27
- · Reporting person: Weinstein Benjamin · Sole voting: 1,105,720 · Shared voting: 1,105,720 · Sole dispositive: 1,105,720 · Shared dispositive: 1,105,720 · SCHEDULE 13G/A, 2026-08-24
- · Reporting person: Empery Asset Management, LP · Sole voting: 0 · Shared voting: 1,314,393 · Sole dispositive: 0 · Shared dispositive: 1,314,393 · SCHEDULE 13G/A, 2026-07-29
- · Reporting person: Lynx1 Capital Management LP · Sole voting: 0 · Shared voting: 1,390,611 · Sole dispositive: 0 · Shared dispositive: 1,390,611 · SCHEDULE 13G, 2026-07-20
Precision BioSciences, Inc. has 17 Schedule 13D or 13G filings on record since 2025-08-06. 6 holders' latest filing reports 5% or more of common stock, $0.000005 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 9.4% | 1,119,311 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 | |
| Aberdeen Group plc | 8.88% | 2,138,603 | SCHEDULE 13G, 2026-01-27 | 2025-12-31 |
| Bleichroeder LP | 8.21% | 1,900,000 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| Octagon Capital Advisors LP | 5.73% | 1,651,497 | SCHEDULE 13G/A, 2026-11-03 | 2026-09-30 |
| Lynx1 Capital Management LP | 5.4% | 1,390,611 | SCHEDULE 13G, 2026-07-20 | 2026-07-13 |
| BlackRock, Inc. | 5.01% | 1,384,230 | SCHEDULE 13G, 2026-10-27 | 2026-09-30 |
| Empery Asset Management, LP | 4.99% | 1,314,393 | SCHEDULE 13G/A, 2026-07-29 | 2026-06-30 |
| 4% | 1,105,720 | SCHEDULE 13G/A, 2026-08-24 | 2026-08-21 | |
| Novartis Pharma AG | 3.7% | 413,581 | SCHEDULE 13G/A, 2025-08-06 | 2025-06-30 |
| Aquilo Capital, L.P. | 0% | 0 | SCHEDULE 13G/A, 2025-08-06 | 2025-06-30 |
| Tang Capital Management, LLC | 0% | 0 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Holding shares or following this stake? See who's behind Precision BioSciences, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Precision BioSciences, Inc. and the records around it.
Precision BioSciences, Inc. elsewhere on the record
- Leadership changes Jul 2026
- Who owns it
Companies that share a holder
- Readout Capital, LP also filed stake reports on 1 other company: TScan Therapeutics, Inc. (Sep 2026)
- Octagon Capital Advisors LP also filed stake reports on 8 other companies: Context Therapeutics Inc. (Jul 2026), Corbus Pharmaceuticals Holdings, Inc. (May 2026), Dianthus Therapeutics, Inc. /DE/ (May 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)
Watch Precision BioSciences, Inc.
Get an email when Precision BioSciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Precision BioSciences, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Precision BioSciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Precision BioSciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Octagon Capital Advisors LP | 0 | 1,651,497 | 0 | 1,651,497 | SCHEDULE 13G/A, 2026-11-03 |
| Octagon Investments Master Fund LP | 0 | 1,651,497 | 0 | 1,651,497 | SCHEDULE 13G/A, 2026-11-03 |
| Ting Jia | 0 | 1,651,497 | 0 | 1,651,497 | SCHEDULE 13G/A, 2026-11-03 |
| Lynx1 Capital Management LP | 0 | 1,390,611 | 0 | 1,390,611 | SCHEDULE 13G, 2026-07-20 |
| Weston Nichols | 0 | 1,390,611 | 0 | 1,390,611 | SCHEDULE 13G, 2026-07-20 |
| BlackRock, Inc. | 1,349,236 | 0 | 1,384,230 | 0 | SCHEDULE 13G, 2026-10-27 |
| Empery Asset Management, LP | 0 | 1,314,393 | 0 | 1,314,393 | SCHEDULE 13G/A, 2026-07-29 |
| Ryan M. Lane | 0 | 1,314,393 | 0 | 1,314,393 | SCHEDULE 13G/A, 2026-07-29 |
| Weinstein Benjamin | 1,105,720 | 1,105,720 | 1,105,720 | 1,105,720 | SCHEDULE 13G/A, 2026-08-24 |
The latest filing identifies Precision BioSciences, Inc. by CUSIP 74019P207 and gives its principal executive office as 302 East Pettigrew Street, Suite A-100, Durham, NC 27701 (SCHEDULE 13G/A, 2026-11-03).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-06 | Novartis Pharma AG | 3.7% | SCHEDULE 13G/A |
| 2025-08-06 | Aquilo Capital, L.P. | 0% | SCHEDULE 13G/A |
| 2025-08-14 | Matthew Smith | 9.4% | SCHEDULE 13G/A |
| 2025-08-14 | Bleichroeder LP | 9.69% | SCHEDULE 13G |
| 2025-11-14 | Lynx1 Capital Management LP | 8.8% | SCHEDULE 13G/A |
| 2026-01-22 | Empery Asset Management, LP | 9.99% | SCHEDULE 13G |
| 2026-01-27 | Aberdeen Group plc | 8.88% | SCHEDULE 13G |
| 2026-02-10 | Octagon Capital Advisors LP | 9.99% | SCHEDULE 13G |
| 2026-02-13 | Bleichroeder LP | 8.21% | SCHEDULE 13G/A |
| 2026-02-17 | Lynx1 Capital Management LP | 4.1% | SCHEDULE 13G/A |
| 2026-02-17 | Tang Capital Management, LLC | 0% | SCHEDULE 13G/A |
| 2026-04-15 | Empery Asset Management, LP | 7.63% | SCHEDULE 13G/A |
| 2026-07-20 | Lynx1 Capital Management LP | 5.4% | SCHEDULE 13G |
| 2026-07-29 | Empery Asset Management, LP | 4.99% | SCHEDULE 13G/A |
| 2026-08-24 | Weinstein Benjamin | 4% | SCHEDULE 13G/A |
| 2026-10-27 | BlackRock, Inc. | 5.01% | SCHEDULE 13G |
| 2026-11-03 | Octagon Capital Advisors LP | 5.73% | SCHEDULE 13G/A |
Questions about who owns Precision BioSciences, Inc.
Who owns Precision BioSciences, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Precision BioSciences, Inc.: Matthew Smith (9.4%, Schedule 13G/A, filed 2025-08-14), Aberdeen Group plc (8.88%, Schedule 13G, filed 2026-01-27), Bleichroeder LP (8.21%, Schedule 13G/A, filed 2026-02-13), Octagon Capital Advisors LP (5.73%, Schedule 13G/A, filed 2026-11-03) and Lynx1 Capital Management LP (5.4%, Schedule 13G, filed 2026-07-20); 1 more is listed above.
Who are the largest shareholders of Precision BioSciences, Inc.?
By the share each holder's latest filing reports, the largest holders of Precision BioSciences, Inc. on this page are Matthew Smith (9.4%), Aberdeen Group plc (8.88%) and Bleichroeder LP (8.21%).
When did Matthew Smith buy into Precision BioSciences, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Matthew Smith on this page is the Schedule 13G/A, filed 2025-08-14, reporting 9.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 17 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Precision BioSciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 27, 2026 | Leadership change: Alex Kelly appointed, Chief Operating Officer, and 2 more | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Precision BioSciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.